Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
hemophilia
Pharma
As Pfizer bows out, CSL keeps hemophilia gene therapy hopes alive
A small patient population, a wait-and-see attitude and a “fairly significant” infrastructure barrier have slowed CSL's gene therapy rollout.
Angus Liu
Apr 11, 2025 10:32am
Sanofi scores FDA nod for Qfitlia for all types of hemophilia
Mar 28, 2025 3:21pm
Amid ongoing launches, Novo eyes rare disease leadership
Mar 7, 2025 9:20am
Pfizer empties gene therapy portfolio, discontinuing Beqvez
Feb 21, 2025 10:48am
Novo at last scores US green light for daily hemophilia med
Dec 23, 2024 10:33am
Novo Nordisk to build $1.2B rare disease drug factory in Denmark
Dec 16, 2024 10:26am
 resize.jpg?VersionId=xqZRoAgddGv5oDcof4BTLR_AkI0X48c_)